(Q46958362)

English

High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study

scientific article published in November 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17926331

High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17926331

metastatic breast cancer

1 reference

based on heuristic

inferred from title

object named as

Ramon Colomer

1

0 references

3

object named as

Belen Lloveras

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17926331

author name string

Antonio Llombart-Cussac

2

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17926331

Manuel Ramos

4

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17926331

Jose I Mayordomo

5

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17926331

Roberto Fernández

6

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17926331

Ignasi Tusquets

7

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17926331

Miguel Gil

8

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17926331

Agustí Barnadas

9

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17926331

Manuel Constenla

10

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17926331

Montserrat Gilabert

11

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17926331

Emilio Alba

12

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17926331

language of work or name

0 references

publication date

1 November 2007

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17926331

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17926331

110

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17926331

10

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17926331

2178-2185

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17926331

In vitro and in vivo release of soluble erbB-2 protein from human carcinoma cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23043

21 January 2018

William L. McGuire Memorial Symposium. The role of erbB2 signal transduction pathways in human breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23043

7 January 2021

based on heuristic

inferred from DOI database lookup

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23043

7 January 2021

based on heuristic

inferred from DOI database lookup

Potential Clinical Utility of Serum HER-2/neu Oncoprotein Concentrations in Patients with Breast Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23043

7 January 2021

based on heuristic

inferred from DOI database lookup

Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23043

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23043

7 January 2021

based on heuristic

inferred from DOI database lookup

Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23043

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23043

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum HER-2/neu and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23043

7 January 2021

based on heuristic

inferred from DOI database lookup

Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23043

7 January 2021

based on heuristic

inferred from DOI database lookup

Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23043

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23043

7 January 2021

based on heuristic

inferred from DOI database lookup

C-erb-b2/int-2 amplification appears faster in breast-cancer patients receiving second-line endocrine treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23043

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23043

7 January 2021

based on heuristic

inferred from DOI database lookup

Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23043

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23043

7 January 2021

based on heuristic

inferred from DOI database lookup

Algorithm for the diagnosis of HER-2/neu status in breast-infiltrating carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23043

7 January 2021

based on heuristic

inferred from DOI database lookup

Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23043

7 January 2021

based on heuristic

inferred from DOI database lookup

Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23043

7 January 2021

based on heuristic

inferred from DOI database lookup

Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23043

7 January 2021

based on heuristic

inferred from DOI database lookup

Challenges in the treatment of bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23043

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.23043

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17926331

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17926331

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46958362&oldid=2139698910"